Maziar Mike Doustdar, who was named as Novo Nordisk’s new CEO last week, spoke on a second quarter earnings call of ...

Novo Nordisk today announced that Maziar Mike Doustdar has been appointed as president and chief executive officer, effective ...

Partially as a result, Novo Nordisk stock has steadily declined since last summer. Over the past year, NVO shares are down ...

Novo Nordisk has appointed Maziar Mike Doustdar as CEO, replacing Lars Fruergaard, to address recent market challenges.

The maker of Ozempic and Wegovy has declared war on “fake” copycat weight-loss jabs as it battles a sales slowdown.

Wegovy-maker Novo Nordisk reported second-quarter sales up 18% on Wednesday, below initial analyst expectations, after a ...

Effective August 7, 2025, Maziar Mike Doustdar will succeed Lars Fruergaard Jørgensen as Novo Nordisk president and chief ...

Novo, valued at $650 billion in June last year, has shed over two-thirds of its value since. Its latest market cap is around ...

Novo Nordisk is to cut costs as the Wegovy-maker battles competition from rival Eli Lilly and copycat versions of its obesity ...

Bagsværd, Denmark, 29 July 2025 - Novo Nordisk today announced that Maziar Mike Doustdar has been appointed as president and chief executive officer, effective 7 August 2025. Mike Doustdar succeeds La ...

July 29 (UPI) -- Novo Nordisk announced Tuesday that Mike Doustdar has been appointed as the company's new CEO. Doustdar ...

When Novo Nordisk A/S announced it was hunting for a replacement chief executive officer to revive its fortunes, the weight-loss drug maker — whose value has dropped by about two thirds in the past ...